The Experts below are selected from a list of 1179 Experts worldwide ranked by ideXlab platform

New York - One of the best experts on this subject based on the ideXlab platform.

  • SEVERE BONE-MARROW DEPRESSION FOLLOWING Arsphenamine; REPORT OF TWO CASES WITH RECOVERY *
    2016
    Co-Authors: Abraham Lieberson, Arthur Weiss, New York
    Abstract:

    T H E authors delayed reporting the following two cases of Arsphenamine bone-marrow depression for several years in order to make certain of the permanency of the recovery which occurred in both cases. The blood dys-pasias occasionally caused by Arsphenamine have been reported in the litera-ture mainly under the headings of their outstanding clinical manifestations, such as granulocytopenia, agranulocytosis, thrombocytopenia, or aplastic anemia. A study of these reports and of the two patients who were fol-lowed carefully on the wards of Beth Israel Hospital has confirmed our belief that most cases may best be considered as early or late instances of the same toxic process which in its severest form causes complete aplasia of the bone-marrow

Abraham Lieberson - One of the best experts on this subject based on the ideXlab platform.

  • SEVERE BONE-MARROW DEPRESSION FOLLOWING Arsphenamine; REPORT OF TWO CASES WITH RECOVERY *
    2016
    Co-Authors: Abraham Lieberson, Arthur Weiss, New York
    Abstract:

    T H E authors delayed reporting the following two cases of Arsphenamine bone-marrow depression for several years in order to make certain of the permanency of the recovery which occurred in both cases. The blood dys-pasias occasionally caused by Arsphenamine have been reported in the litera-ture mainly under the headings of their outstanding clinical manifestations, such as granulocytopenia, agranulocytosis, thrombocytopenia, or aplastic anemia. A study of these reports and of the two patients who were fol-lowed carefully on the wards of Beth Israel Hospital has confirmed our belief that most cases may best be considered as early or late instances of the same toxic process which in its severest form causes complete aplasia of the bone-marrow

Arthur Weiss - One of the best experts on this subject based on the ideXlab platform.

  • SEVERE BONE-MARROW DEPRESSION FOLLOWING Arsphenamine; REPORT OF TWO CASES WITH RECOVERY *
    2016
    Co-Authors: Abraham Lieberson, Arthur Weiss, New York
    Abstract:

    T H E authors delayed reporting the following two cases of Arsphenamine bone-marrow depression for several years in order to make certain of the permanency of the recovery which occurred in both cases. The blood dys-pasias occasionally caused by Arsphenamine have been reported in the litera-ture mainly under the headings of their outstanding clinical manifestations, such as granulocytopenia, agranulocytosis, thrombocytopenia, or aplastic anemia. A study of these reports and of the two patients who were fol-lowed carefully on the wards of Beth Israel Hospital has confirmed our belief that most cases may best be considered as early or late instances of the same toxic process which in its severest form causes complete aplasia of the bone-marrow

John Parascandola - One of the best experts on this subject based on the ideXlab platform.

  • history of salvarsan Arsphenamine
    eLS, 2001
    Co-Authors: John Parascandola
    Abstract:

    The drug Salvarsan (Arsphenamine) was developed and introduced as a chemotherapeutic agent against syphilis in the first decade of the twentieth century by Paul Ehrlich. Although a significant breakthrough in the treatment of syphilis at the time, it was eventually replaced by penicillin. Keywords: chemotherapy; Ehrlich; pharmacology; syphilis; therapeutics

  • eLS - History of Salvarsan (Arsphenamine)
    Encyclopedia of Life Sciences, 2001
    Co-Authors: John Parascandola
    Abstract:

    The drug Salvarsan (Arsphenamine) was developed and introduced as a chemotherapeutic agent against syphilis in the first decade of the twentieth century by Paul Ehrlich. Although a significant breakthrough in the treatment of syphilis at the time, it was eventually replaced by penicillin. Keywords: chemotherapy; Ehrlich; pharmacology; syphilis; therapeutics

Graham Bruce - One of the best experts on this subject based on the ideXlab platform.

  • THE USE OF NEOArsphenamine IN THE TREATMENT OF AMEBIC DYSENTERY *
    2016
    Co-Authors: Graham Bruce
    Abstract:

    THIS is to report 15 cases of amebic dysentery treated with neoarsphen-amine intravenously during the Japanese internment of American Prisoners of War at Camp No. 1, Cabanatuan, Philippine Islands. This drug was not the drug of choice but rather the only drug at hand before the arrival of Red Cross medical supplies in December, 1943. Although neoarsphen-amine had never been used to any appreciable extent for amebiasis, it was felt that the arsenic derived therefrom should be effective in eradicating the ameba and cysts. Arsenic is also a well known alterative, and it was be-lieved that it would stimulate the appetite which was later found to be true. Up to 1935, in a review of cases of amebiasis treated at the Mayo Clinic, it is stated that 38 patients received Arsphenamine with no untoward reac-tions.1 Six weekly doses of Arsphenamine were given in those instances in which carbarsone, vioform or other drugs had failed to eradicate the ameba. An in vitro study of mapharsen and seven other compounds has been recently conducted.2 It was found that of the group of chemicals studied